Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 247

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 247
---
 to audit our financial statements; |

| ● | helping to ensure the independence                                    
 and performance of the independent registered public accounting firm; |

| ● | discussing the scope and results                                                                                                     
 of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, 
 our annual audited financial statements and quarterly financial statements;                                                          |

| ● | developing procedures for employees                                            
 to submit concerns anonymously about questionable accounting or audit matters; |

| ● | reviewing and discussing policies       
 on risk assessment and risk management; |

| ● | reviewing related party transactions; |

| ● | obtaining and reviewing a report                                                                                                            
 by the independent registered public accounting firm at least annually that describes the internal quality-control procedures, any material 
 issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and                              |

| ● | approving (or, as permitted,                                                                                                         
 pre-approving) all audit and all permissible non-audit service to be performed by the independent registered public accounting firm. |

Compensation Committee The members of our Compensation Committee are Ms. LaPorte, Dr. Rolfe and Mr. Patel. Ms. LaPorte serves as the chairperson of the Compensation Committee. Our board of directors has determined that each of Ms. LaPorte, Dr. Rolfe and Mr. Patel is independent under the applicable Nasdaq listing standards and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act. Our Compensation Committee’s main function is to oversee our compensation structure, policies and programs and to review the processes and procedures for the consideration and determination of director and executive compensation. The Compensation Committee’s responsibilities include, among other things:

| ● | recommending to the board of                                                                       
 directors goals and objectives, non-equity compensation, and equity grants of all senior officers; |

| ● | recommending to the board of                                                                                
 directors goals and objectives, non-equity compensation, and equity grants for the Chief Executive Officer; |

| ● | recommending to the board of                                           
 directors non-equity compensation and equity grants for the directors; |

| ● | reviewing and discussing with                                                                       
 the board of directors corporate succession plans for the Chief Executive Officer and key officers; |

| ● | reviewing and discussing with                              
 management its talent development and related initiatives; |

| ● | assisting the board of directors                                                                                                            
 with its oversight of our strategies, programs, and initiatives related to employee health, safety, and well-being,